JP2016506417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506417A5 JP2016506417A5 JP2015552755A JP2015552755A JP2016506417A5 JP 2016506417 A5 JP2016506417 A5 JP 2016506417A5 JP 2015552755 A JP2015552755 A JP 2015552755A JP 2015552755 A JP2015552755 A JP 2015552755A JP 2016506417 A5 JP2016506417 A5 JP 2016506417A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- groups
- unsubstituted
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 36
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 20
- 238000000034 method Methods 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 210000001147 pulmonary artery Anatomy 0.000 claims 12
- 230000004872 arterial blood pressure Effects 0.000 claims 10
- 208000002815 pulmonary hypertension Diseases 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 229910052731 fluorine Inorganic materials 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000004104 aryloxy group Chemical group 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- -1 guanidinyl groups Chemical group 0.000 claims 6
- 229910052740 iodine Inorganic materials 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 230000001965 increasing effect Effects 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 claims 4
- 102000012085 Endoglin Human genes 0.000 claims 4
- 108010036395 Endoglin Proteins 0.000 claims 4
- 206010020880 Hypertrophy Diseases 0.000 claims 4
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims 4
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 230000009885 systemic effect Effects 0.000 claims 4
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 claims 3
- 206010021143 Hypoxia Diseases 0.000 claims 3
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 3
- 230000007954 hypoxia Effects 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 3
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 3
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 2
- 201000006306 Cor pulmonale Diseases 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 2
- 208000015872 Gaucher disease Diseases 0.000 claims 2
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 claims 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims 2
- 241000257303 Hymenoptera Species 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010021133 Hypoventilation Diseases 0.000 claims 2
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 206010049459 Lymphangioleiomyomatosis Diseases 0.000 claims 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 2
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 206010071436 Systolic dysfunction Diseases 0.000 claims 2
- 208000024799 Thyroid disease Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 2
- 208000028831 congenital heart disease Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000009547 development abnormality Effects 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000007345 glycogen storage disease Diseases 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000007475 hemolytic anemia Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 229940001447 lactate Drugs 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 230000004199 lung function Effects 0.000 claims 2
- 229940049920 malate Drugs 0.000 claims 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 201000004931 neurofibromatosis Diseases 0.000 claims 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 210000003492 pulmonary vein Anatomy 0.000 claims 2
- 230000009467 reduction Effects 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000004409 schistosomiasis Diseases 0.000 claims 2
- 238000010911 splenectomy Methods 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 206010065553 Bone marrow failure Diseases 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 108010078321 Guanylate Cyclase Proteins 0.000 claims 1
- 102000014469 Guanylate cyclase Human genes 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 1
- 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 claims 1
- 208000021085 Pulmonary hypertension with unclear multifactorial mechanism Diseases 0.000 claims 1
- 108091005682 Receptor kinases Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 229940127282 angiotensin receptor antagonist Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 230000037147 athletic performance Effects 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000009084 cardiovascular function Effects 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 230000023753 dehiscence Effects 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- 229940127293 prostanoid Drugs 0.000 claims 1
- 150000003814 prostanoids Chemical class 0.000 claims 1
- 230000009325 pulmonary function Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 230000035488 systolic blood pressure Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361751217P | 2013-01-10 | 2013-01-10 | |
| US61/751,217 | 2013-01-10 | ||
| PCT/US2014/010773 WO2014110198A2 (en) | 2013-01-10 | 2014-01-09 | Therapeutic indications of kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016506417A JP2016506417A (ja) | 2016-03-03 |
| JP2016506417A5 true JP2016506417A5 (enExample) | 2016-04-14 |
Family
ID=51167503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015552755A Pending JP2016506417A (ja) | 2013-01-10 | 2014-01-09 | キナーゼ阻害剤の治療指標 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20150352111A1 (enExample) |
| EP (1) | EP2988738A4 (enExample) |
| JP (1) | JP2016506417A (enExample) |
| AU (1) | AU2014205481A1 (enExample) |
| CA (1) | CA2897538A1 (enExample) |
| WO (1) | WO2014110198A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3007689T3 (en) * | 2013-01-10 | 2018-06-14 | Pulmokine Inc | NON-SELECTIVE KINASE INHIBITORS |
| ES2959419T3 (es) * | 2013-10-11 | 2024-02-26 | Pulmokine Inc | Formulaciones secas por aspersión |
| US10471059B2 (en) * | 2015-01-26 | 2019-11-12 | Yale University | Compositions and methods of using tyrosine kinase inhibitors |
| BR112019008622A2 (pt) | 2016-10-27 | 2019-07-09 | Pulmokine Inc | método para tratar uma condição |
| SG11202112719XA (en) * | 2019-05-16 | 2021-12-30 | Aerovate Therapeutics Inc | Imatinib formulations, manufacture, and uses thereof |
| US20240325390A1 (en) * | 2020-11-23 | 2024-10-03 | Aerovate Therapeutics, Inc. | Imatinib formulations, manufacture, and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPS251502A0 (en) * | 2002-05-23 | 2002-06-13 | Cytopia Pty Ltd | Protein kinase inhibitors |
| CN100558715C (zh) * | 2002-05-23 | 2009-11-11 | 西托匹亚有限公司 | 蛋白激酶抑制剂 |
| PT1689715E (pt) * | 2003-12-03 | 2011-05-16 | Ym Biosciences Australia Pty | Inibidores da tubulina |
| WO2007087575A2 (en) * | 2006-01-24 | 2007-08-02 | University Of Chicago | Compositions and methods for treating pulmonary hypertension |
| WO2007101232A2 (en) * | 2006-02-28 | 2007-09-07 | Cytopia Research Pty, Ltd. | Inhibition of jak2 as a treatment of pulmonary arterial hypertension |
| EP3048099A3 (en) * | 2006-11-15 | 2016-09-21 | YM BioSciences Australia Pty Ltd | Inhibitors of kinase activity |
| DK3007689T3 (en) * | 2013-01-10 | 2018-06-14 | Pulmokine Inc | NON-SELECTIVE KINASE INHIBITORS |
-
2014
- 2014-01-09 JP JP2015552755A patent/JP2016506417A/ja active Pending
- 2014-01-09 EP EP14737772.5A patent/EP2988738A4/en not_active Withdrawn
- 2014-01-09 US US14/760,165 patent/US20150352111A1/en not_active Abandoned
- 2014-01-09 CA CA2897538A patent/CA2897538A1/en not_active Abandoned
- 2014-01-09 AU AU2014205481A patent/AU2014205481A1/en not_active Abandoned
- 2014-01-09 WO PCT/US2014/010773 patent/WO2014110198A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506418A5 (enExample) | ||
| JP2016506417A5 (enExample) | ||
| US20220008436A1 (en) | Treprostinil administration by inhalation | |
| CN1196479C (zh) | 吸入形式的苯并茚前列腺素制剂的用途 | |
| JP2025016462A (ja) | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター | |
| KR20160061994A (ko) | 바독솔론 메틸 또는 이의 유사체를 이용한 내피 기능장애의 치료 및 예방 방법 | |
| JP2014077003A5 (enExample) | ||
| US20160166556A1 (en) | Methods of treating pulmonary hypertension | |
| US11141422B2 (en) | Methods for treating pulmonary hypertension | |
| JP2013237683A (ja) | 肺高血圧症の治療のためのロフルミラスト | |
| JP2013528649A (ja) | 肺高血圧症の処置のために使用するためのラノラジン | |
| CN103582481A (zh) | A2b腺苷受体拮抗剂用于治疗心肌梗塞后患者的心力衰竭及心律不齐的用途 | |
| US9827211B2 (en) | Uses and methods for the treatment of liver diseases or conditions | |
| KR20210126515A (ko) | 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물 | |
| US20250073208A1 (en) | Il-6 and/or il-1beta inhibitor | |
| US20260000647A1 (en) | Compositions, Formulations, And Methods Of Treating Neurodegenerative Diseases | |
| Blythe et al. | Pulmonary hypertension and selective pulmonary vasodilators in acute lung injury | |
| US11413273B2 (en) | Prophylactic or therapeutic agent for pulmonary hypertension comprising unsaturated 5-membered heterocycle-containing compound | |
| JPWO2023126437A5 (enExample) | ||
| Daoud et al. | Effects of airway pressure release ventilation on extra vascular lung water in acute lung injury and acute respiratory distress syndrome. | |
| RU2292889C2 (ru) | Способ лечения системной и легочной артериальной гипертензии у больных хроническим обструктивным бронхитом и бронхиальной астмой | |
| US20020115661A1 (en) | Method for treating chronic obstructive pulmonary disease | |
| Lango et al. | High-volume hemofiltration as adjuvant therapy for refractory shock after pericardiocentesis | |
| Waechter et al. | Scleroderma, The Prone Position and Profound Hypotension: A Case Report | |
| CN106692976A (zh) | P‑糖蛋白抑制剂Gelucire44/14作为经口服的盐酸小檗碱吸收促进剂的应用 |